Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 3
1994 2
1995 6
1996 12
1997 9
1998 10
1999 1
2000 2
2001 1
2002 3
2003 1
2005 1
2010 3
2011 3
2012 2
2013 12
2014 1
2018 1
2019 2
2020 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

71 results
Results by year
Filters applied: . Clear all
Page 1
GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.
Sterner RM, Sakemura R, Cox MJ, Yang N, Khadka RH, Forsman CL, Hansen MJ, Jin F, Ayasoufi K, Hefazi M, Schick KJ, Walters DK, Ahmed O, Chappell D, Sahmoud T, Durrant C, Nevala WK, Patnaik MM, Pease LR, Hedin KE, Kay NE, Johnson AJ, Kenderian SS. Sterner RM, et al. Among authors: sahmoud t. Blood. 2019 Feb 14;133(7):697-709. doi: 10.1182/blood-2018-10-881722. Epub 2018 Nov 21. Blood. 2019. PMID: 30463995 Free PMC article.
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN. Baselga J, et al. Among authors: sahmoud t. N Engl J Med. 2012 Feb 9;366(6):520-9. doi: 10.1056/NEJMoa1109653. Epub 2011 Dec 7. N Engl J Med. 2012. PMID: 22149876 Free PMC article. Clinical Trial.
Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial.
Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, Sauter M, Nonomura N, Brakemeier S, de Vries PJ, Whittemore VH, Chen D, Sahmoud T, Shah G, Lincy J, Lebwohl D, Budde K. Bissler JJ, et al. Among authors: sahmoud t. Lancet. 2013 Mar 9;381(9869):817-24. doi: 10.1016/S0140-6736(12)61767-X. Lancet. 2013. PMID: 23312829 Clinical Trial.
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Whittemore VH, Thiele EA, Ford JP, Shah G, Cauwel H, Lebwohl D, Sahmoud T, Jozwiak S. Franz DN, et al. Among authors: sahmoud t. Lancet. 2013 Jan 12;381(9861):125-32. doi: 10.1016/S0140-6736(12)61134-9. Epub 2012 Nov 14. Lancet. 2013. PMID: 23158522 Clinical Trial.
Estimation of COVID-19 burden in Egypt.
Sahmoud T. Sahmoud T. Lancet Infect Dis. 2020 Aug;20(8):895-896. doi: 10.1016/S1473-3099(20)30318-2. Epub 2020 Apr 27. Lancet Infect Dis. 2020. PMID: 32353348 Free PMC article. No abstract available.
Current and future perspectives on fulvestrant.
Gradishar WJ, Sahmoud T. Gradishar WJ, et al. Among authors: sahmoud t. Clin Breast Cancer. 2005 Apr;6 Suppl 1:S23-9. doi: 10.3816/cbc.2005.s.011. Clin Breast Cancer. 2005. PMID: 15865847
Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.
Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN. Krueger DA, et al. Among authors: sahmoud t. N Engl J Med. 2010 Nov 4;363(19):1801-11. doi: 10.1056/NEJMoa1001671. N Engl J Med. 2010. PMID: 21047224 Free article. Clinical Trial.
71 results